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Abstract. Living donor liver transplantation (LDLT) requires 
ischemia/reperfusion (I/R), which can cause early graft injury. 
However, the detailed mechanism of I/R injury remains 
unknown. Heme oxygenase-1 (HO-1) is a rate-limiting enzyme 
in heme catabolism and results in the production of iron, 
carbon monoxide (CO), and biliverdin IXα. Furthermore, in 
animals, HO-1 has a protective effect against oxidative stress 
associated with I/R injury. However, in humans, the molecular 
mechanism and clinical significance of HO-1 remain unclear. 
We previously demonstrated that exhaled CO levels increase 
during LDLT, and postulated that this may indicate I/R injury. 
In this study, we elucidate the origin of increased exhaled CO 
levels and the role of HO-1 in I/R injury during LDLT. We 
studied 29 LDLT donors and recipients each. For investiga-
tion of HO-1 gene expression by polymerase chain reaction 
and HO-1 localization by immunohistological staining, liver 
biopsies from the grafted liver were conducted twice, once 
before and once after I/R. Exhaled CO levels and HO-1 gene 
expression levels significantly increased after I/R. In addi-
tion, HO-1 levels significantly increased after I/R in Kupffer 
cells. Furthermore, we found a significant positive correlation 
between exhaled CO levels and HO-1 gene expression levels. 
These results indicated that increased heme breakdown in the 
grafted liver is the source of increased exhaled CO levels. 
We also found a significant relationship between HO-1 gene 
expression levels and alanine aminotransferase (ALT) levels; 
i.e., the higher the HO-1 gene expression levels, the higher the 
ALT levels. These results suggest that HO-1-mediated heme 
breakdown is caused by I/R during LDLT, since it is associ-
ated with increased exhaled CO levels and liver damage.
Introduction
Recently, liver transplantation has become a common thera-
peutic method for end-stage liver diseases such as liver cirrhosis 
with or without hepatocellular carcinoma and fulminant 
hepatitis (1). However, a major problem with this method is the 
shortage of donor organs. One of the solutions to this problem is 
living donor liver transplantation (LDLT). LDLT requires cold 
preservation and warm revascularization of liver grafts during 
transplantation. However, injuries due to ischemia/reperfusion 
(I/R), which is known to induce oxidative stress, are unavoid-
able during LDLT (2,3).
The rate-limiting enzyme in heme catabolism, heme 
oxygenase-1 (HO-1), is induced by not only its substrate heme 
but also oxidative stress resulting from I/R injury (4-7). HO-1 
induction leads to increased heme breakdown, resulting in the 
production of iron, carbon monoxide (CO), and biliverdin IXα, 
which is subsequently reduced to bilirubin IXα by biliverdin 
reductase (7,8). According to our previous reports, HO-1 has a 
protective effect against oxidative stress, as seen in carbon tetra-
chloride-induced liver injury models (9,10). Other investigators 
have also reported similar protective effects of HO-1 in animals 
(11,12). In humans, patients with acute liver hepatitis showed 
increased HO-1 and decreased nonspecific δ-aminolevulinate 
synthase (ALAS-1) gene expression levels, which is the rate-
limiting enzyme in heme biosynthesis (13). However, the 
molecular mechanism responsible for increased HO-1 expres-
sion levels and its clinical significance remains unclear.
We previously demonstrated that exhaled CO levels 
increased in LDLT recipients after I/R injury, and suggested 
that exhaled CO levels indicate the extent of oxidative tissue 
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injury in the affected organ (14). However, the origin of exhaled 
CO remains unknown.
In this study, we hypothesized that the source of increased 
exhaled CO is related to heme breakdown induced by HO-1 
after I/R injury. We also investigated the clinical significance 
of HO-1 in the grafted liver during LDLT. Therefore, we 
investigated HO-1 gene and protein expression levels and their 
relationship with exhaled CO levels and liver injury in 29 
grafted livers during LDLT.
Materials and methods
Patients. This study was conducted in accordance with the 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Okayama University Hospital. We prospec-
tively studied 29 (16 male, 13 female) patients who had 
undergone LDLT between 2006 and 2008 at Okayama 
University Hospital. Informed consent was obtained from all 
participants.
Anesthetic procedure. All surgeries were performed under 
general anesthesia. Each patient received 2 mg/kg of propofol, 
5 µg/kg of fentanyl or approximately 0.3 µg/kg/min of remifen-
tanil, and 0.1 mg/kg of vecuronium to facilitate endotracheal 
intubation. Anesthesia was maintained using a continuous 
infusion of remifentanil and vecuronium at a rate of 0.1-0.5 µg/
kg/min and 2-4 mg/kg/h, respectively, along with 0.5-1.0% of 
isoflurane in an oxygen/air mixture.
Transplantation procedure. The donor and recipient hepatec-
tomies were performed using a standard technique (15). The 
grafted liver was weighted and perfused through the portal 
vein using University of Wisconsin (UW) solution with 
methyl-prednisolone. Portal flush was performed by gravity. 
After perfusion, the graft was immersed in the UW solution 
and stored at 4˚C. The graft was transplanted using the piggy-
back technique. Before completion of caval anastomosis, the 
graft was flushed through the portal vein with about 250 ml of 
5% albumin stored at 4˚C. Hepatic artery reconstruction was 
performed by end-to-end anastomosis and biliary duct recon-
struction was performed by duct-to-duct anastomosis (16).
Exhaled CO measurement. Exhaled CO levels were measured 
using a CO analyzer (Carbolyzer™ mBA-2000, Taiyo 
Instruments, Inc., Osaka, Japan), as described previously 
(14). The instrument had a sensitivity of 0.1 ppm CO and 
was capable of continuous side stream sampling. A sampling 
adaptor was attached to the respiratory circuit for exhaled air 
sampling. Anesthetic drugs with muscle relaxants maintained 
constant respiratory conditions throughout the procedure. 
Throughout the anesthetic period, we controlled the respira-
tory rate, partial pressure of oxygen in arterial blood, partial 
pressure of carbon dioxide in arterial blood, and pH within 
normal ranges by taking periodic measurements of arterial 
blood gas samples. Although there were small fluctuations 
after normalization, CO levels were essentially constant and 
stable, and time courses were comparable among all indi-
viduals. During anesthesia, exhaled CO levels were measured 
twice, once after induction and once after reperfusion.
Liver biopsy. Liver biopsies were performed from the donors 
just before graft resection. The same amount of tissue was taken 
from the grafted liver of recipients just before skin closure to 
assess the effects of I/R. Just after liver biopsy, we divided the 
samples into two pieces, one was frozen in liquid nitrogen for 
Table I. Primer pairs used for polymer chain reaction.
Target cDNA Accession no.  Primer sequence (5'→3') Amplicon size (bp)
β-actin NM_001101 Forward: GTGGCATCCACGAAACTACC 197
  Reverse: GTACTTGCGCTCAGGAGGAG
HO-1 NM_002133 Forward: ATGACACCAAGGACCAGAGC 169
  Reverse: GCCACCAGAAAGCTGAGTGT
ALAS-1 NM_000688 Forward: CACACACCCCAGATGATGAA 108
  Reverse: CCTGCAGAAGTTGCACTCAG
HO-1, heme oxygenase-1; ALAS-1, nonspecific δ-aminolevulinate synthase.
Table II. Patient characteristics.
Patient characteristics na
Age of recipients (years) 40±23
Gender of recipients (male:female) 16:13
Primary disease
  Viral liver cirrhosis 12
  Biliary atresia 7
  Nonalcoholic steatohepatitis 4
  Primary sclerosing cholangtitis 2
  Fulminant hepatitis 1
  Budd-Chiari syndrome 1
  Alcoholic hepatitis 1
  Hepatoblastoma 1
Pre-operation MELD score 15±7
Age of donors (years) 38±14
Gender of donors (male:female) 16:13
aData represent the number of patient (n) or mean ± SD or ratio. 
MELD score, model for end-stage liver disease score.
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assessment of gene expression levels, and the other was fixed 
in 10% neutral buffered formalin for histological examination.
Measurement of HO-1 and ALAS-1 gene expression levels. 
HO-1 and ALAS-1 gene expression levels were measured as 
described previously (17). We extracted messenger ribonucleic 
acid (mRNA) from the liver samples using the RNeasy Mini 
kit (Qiagen, Tokyo, Japan) and constructed complementary 
deoxyribonucleic acid (cDNA) from mRNA using the Ready-
To-Go T-Primed First-Strand kit (Amersham Biosciences, 
Buckinghamshire, UK). Primer sequences are shown in 
Table I. To analyze HO-1 and ALAS-1 gene expression, real-
time polymerase chain reaction was performed using a Light 
Cycler (Roche Diagnostics, Mannheim, Germany).
Immunohistochemistry. HO-1 exists in nonparenchymal 
cells, possibly in the Kupffer cells (18). To identify HO-1, 
immunohistochemical analysis was performed using the 
indirect immunofluorescence method. The liver samples, 
which were fixed in 10% neutral buffered formalin, were 
embedded in paraffin and sectioned at a thickness of 5 µm. 
Following antigen retrieval in citrate buffer (0.01 M, pH 6.0) 
using heat treatment by autoclaving, nonspecific binding sites 
were blocked with 5% normal donkey serum for 60 min. For 
HO-1 staining, slides were incubated at 4˚C overnight with 
polyclonal rabbit HO-1 antibody (StressGen Biotechnologies, 
Victoria, BC, Canada) at a dilution of 1:100 in 1X phosphate-
buffered saline (PBS) containing 0.3% Triton X-100. For 
fluorescent visualization of the bound antibody, the slides were 
incubated with fluorescein isothiocyanate-conjugated donkey 
anti-rabbit IgG (Santa Cruz Biotechnologies, Inc., Santa Cruz, 
CA, USA) and a green fluorescent label for 90 min. To confirm 
HO-1 localization in the liver, CD68 cells where HO-1 was 
assumed to exist were stained. After the nonspecific binding 
sites were blocked by the procedure described above, the 
slides were incubated at 4˚C overnight with anti-CD68 mouse 
monoclonal antibody (Calbiochem, San Diego, CA, USA) at a 
dilution of 1:100 in 1X PBS containing 0.3% Triton X-100. For 
fluorescent visualization of the bound antibody, the slides were 
incubated with rhodamine-conjugated donkey anti-mouse IgG 
(Chemicon International, Billerica, MA, USA) for 90 min. 
Finally, images were acquired using a Zeiss confocal laser 
scanning microscope (LSM510; Zeiss, Jena, Germany).
Postoperative biochemical examinations. To estimate the 
clinical significance of I/R injury, postoperative aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and 
total bilirubin (T.Bil) levels were measured. Tissues for these 
examinations were obtained as routine laboratory samples at 
the time of skin closure of the recipients.
Statistical analysis. Data were expressed as mean and standard 
deviation. The Student's t-test, Pearson's correlation coeffi-
cients, or analysis of variance was used for data analysis. We 
considered P<0.05 to be statistically significant.
Results
We prospectively studied 29 (16 male, 13 female) patients who 
had undergone LDLT between 2006 and 2008. Of these, 12 
patients who had viral liver cirrhosis, 7 had biliary atresia, 4 
had nonalcoholic steatohepatitis, and 2 had primary sclerosing 
cholangitis. One patient had Budd-Chiari syndrome, 1 had 
alcoholic hepatitis, 1 had hepatoblastoma, and 1 had fulminant 
hepatitis. The mean age of the recipients was 40±23 years. The 
mean model for end-stage liver disease (MELD) score for these 
patients was 15±7. The donors were 16 males and 13 females 
whose mean age was 38±14 years. All donors had normal liver 
biochemical findings and T.Bil levels. Liver grafts were of the 
following types: right lobe (n=9), left lobe (n=2), extended right 
Figure 1. Changes of the indices for heme breakdown after Ischemia/reperfusion. (A) The significant increase of exhaled carbon monoxide (CO) after isch-
emia/reperfusion (I/R) injury (P=0.00055). (B) The increase of heme oxygenase (HO)-1 gene expression in the grafted liver after I/R injury (P=0.0000013). 
(C) The tendency of the decrease of nonspecific δ-aminolevulinate synthase (ALAS)-1 gene expression in the grafted liver after I/R injury (P=0.10). These 
results indicated the increase of heme breakdown during living donor liver transplantation.
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lobe (n=2), extended left lobe (n=10) and lateral lobe (n=6). 
The surgery time in the recipients was 559±110 min. Cold 
and warm ischemia times of the grafts were 68.5±36.8 and 
45.6±23.1 min, respectively. The mean graft volume/recipient 
body weight ratio was 1.23±0.73 and blood loss during surgery 
in recipients was 98.2±91.0 ml/kg (Table II).
Pre- and post-reperfusion exhaled CO levels were 3.3±0.9 
and 7.4±2.5 ppm, respectively. Exhaled CO levels significantly 
increased after I/R (P=0.00055) (Fig. 1A). This result was 
almost the same as that in our previous report (14). Pre- and 
post-reperfusion HO-1 gene expression levels were 0.04±0.05 
and 0.13±0.08, respectively. HO-1 gene expression was signifi-
cantly up-regulated after I/R (P=0.0000013) (Fig. 1B). In 
contrast, although this result was not statistically significant 
(P=0.10), ALAS-1 gene expression levels after reperfusion 
decreased compared to that before reperfusion, from 0.50±0.34 
to 0.37±0.40 (Fig. 1C), suggesting that there may be an increase 
in hepatic free heme levels, which leads to the induction of 
HO-1, ultimately resulting in heme catabolism.
To confirm that increased HO-1 gene expression levels 
induce an increase in HO-1, we performed immunohistochem-
ical analysis. Fluorescent analysis revealed that HO-1 levels 
were increased after I/R (Fig. 2A and B). Additionally, we 
verified HO-1 localization in the liver using fluorescent double 
Figure 2. Immunohistochemistry of heme oxygenase-1 and CD68(KP). (A-C) Heme oxygenase (HO)-1 protein in green stained by FTIC. (A and B) HO-1 protein 
in pre- and post-reperfusion, respectively. These results showed the increase of HO-1 protein in the grafted liver after I/R injury. (C-E) The double staining of 
HO-1 protein and CH68 positive cells (Kuppfer cells). HO-1 protein stained in green and CD68 stained in red by rhodamine. (E) HO-1 protein existed in Kuppfer 
cells in the grafted liver in post-reperfusion during living donor liver transplantation.
Figure 3. Relationship between exhaled carbon monoxide and heme oxy-
genase-1 gene expression in post reperfusion. Significant positive correlation 
was observed between exhaled carbon monoxide (CO) and heme oxygenase 
(HO)-1 gene expression in post reperfusion (r2=0.19; P=0.0078). This result 
indicated that exhaled CO was the product from heme metabolized by HO-1.
Figure 4. Relationship between heme oxygenase-1 gene expression and early 
graft function. The analysis of the relationship between heme oxygenase 
(HO)-1 gene expression and early graft function represented by alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST). No significant 
relationship exists between AST and HO-1 (r2=0.058; P=0.21), but there was 
a significant positive correlation between HO-1 gene expression and ALT 
(r2=0.26; P=0.0052). This result indicated that HO-1 gene expression in the 
grafted liver would affect early graft dysfunction after living donor liver 
transplantation.
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staining, which showed that HO-1 and CD68 existed in the 
same cells (Fig. 2C-E). Because the CD68 antigen is specifi-
cally expressed by tissue macrophages, including the Kupffer 
cells, our results verified that HO-1 exist in the Kupffer cells.
Our analysis revealed a significant positive correlation 
between post-reperfusion exhaled CO levels and HO-1 gene 
expression levels (r2=0.19; P=0.0078) (Fig. 3). This result 
indicated that an increase in exhaled CO levels was caused by 
increased heme breakdown in the grafted liver. Furthermore, 
increased HO-1 gene expression levels significantly correlated 
with postoperative ALT levels (r2=0.228; P=0.0052) (Fig. 4A), 
although there were no correlation with AST level (r2=0.058; 
P=0.207) (Fig. 4B) or T.Bil level (r2=0.103; P=0.089) (data not 
shown). These results suggested that HO-1 gene expression 
levels indicate the extent of heme breakdown in the grafted 
liver and results in early graft dysfunction.
Discussion
We conducted a prospective observational study to assess the 
effect of I/R injury during LDLT on exhaled CO levels and 
HO-1 mRNA and protein expression. We also assessed the 
relationship between these indicators and the extent of liver 
damage. First, we found that exhaled CO levels increased 
after I/R during LDLT. Second, HO-1 mRNA expression 
increased in the grafted liver after I/R, and HO-1 increased in 
the Kupffer cells. In contrast, ALAS-1 mRNA expression did 
not increase. Third, there was a relationship between increased 
exhaled CO levels and HO-1 mRNA expression levels. Finally, 
we found a significant relationship between increased HO-1 
gene expression levels and postoperative serum ALT levels.
Increased exhaled CO levels. We found that exhaled CO levels 
significantly increased after I/R during LDLT. This increase 
in exhaled CO levels positively correlated with HO-1 gene 
expression levels in the grafted liver. Previously, we reported 
that exhaled CO levels significantly increased in critically 
ill patients in intensive care units and LDLT recipients after 
reperfusion (14,19). In this study, we again found an increase in 
post-reperfusion exhaled CO levels. To investigate the source 
of this increase, we hypothesized that it may indicate heme 
breakdown caused by oxidative stress caused by I/R injury in 
humans. In our correlation analysis, the increased exhaled CO 
levels correlated significantly with increased HO-1 mRNA 
expression levels in the grafted liver. It is well known that CO 
is one of the three heme metabolites, and that this heme degra-
dation reaction is mediated by HO-1 (20). It is also well known 
that this reaction is the only process to produce endogenous 
CO. Thus, our results and this evidence strongly suggest that 
the source of increased exhaled CO levels after reperfusion is 
the increased heme breakdown in the grafted liver, which is 
mediated by HO-1.
Increased HO-1 mRNA and protein expression levels. HO-1 
gene expression levels in the grafted liver increased significantly, 
but ALAS-1 gene expression levels tended to decrease after I/R. 
Using immunohistochemistry, we confirmed that the increase 
in HO-1 gene expression levels led to an increase in HO-1 in 
the Kupffer cells. To our knowledge, this is the first report that 
confirms the specific site of HO-1 localization in human liver. 
Oxidative stress due to I/R injury causes the breakdown of heme 
proteins and increases free heme levels, which in turn cause 
cell damage. HO-1 catabolizes free heme into CO, biliverdin, 
and iron (20,21). According to many animal studies, HO-1 has 
protective effects against oxidative stress (22-24). We postulated 
that increased HO-1 levels may be indicated by an increase in 
free heme levels caused by I/R. Previous reports showed that 
HO-1 induces heme breakdown in the Kupffer cells in animal 
models using a hemoglobin-based oxygen carrier injection (18). 
We found that HO-1 was expressed in the Kupffer cells. These 
results indicated that the Kupffer cells also play an important 
role in I/R injury through increased HO-1 expression.
HO-1 and outcome. We also assessed the relationship between 
HO-1 induction and postoperative early graft dysfunction. We 
used ALT as a marker of liver injury, since it is believed to be 
associated with HO-1 (9,10,25). In this study, we found a positive 
correlation between HO-1 gene expression levels during LDLT 
and serum ALT levels at the time of skin closure of the recipi-
ents. That is, higher HO-1 induction was associated with more 
severe postoperative early graft dysfunction. Theoretically, 
if injury is severe, more HO-1 is induced in order to protect 
cells. Thus, our finding was quite reasonable. However, we were 
unable to conclude whether HO-1 is effective in protecting 
the cells. Further studies are needed to elucidate the clinical 
implications of HO-1 induction in detail. Ideally, future studies 
should determine whether pharmacological HO-1 induction 
such as that with glutamine can reduce I/R injury after LDLT.
Limitations. This study has several limitations. First, although 
we assumed that free heme would increase after I/R, and 
subsequently HO-1 would be induced, we did not measure free 
heme levels. However, free heme measurement is not possible at 
present. Further technological development is required. Second, 
liver biopsy was only performed twice and graft dysfunction 
was assessed only once. Thus, we only studied time-specific 
abnormality rather than the entire process. A study with a larger 
sample size and longer observation period is required to eluci-
date the process of HO-1 reaction and its clinical significance.
In conclusion, we demonstrated that increased exhaled CO 
levels may be due to heme breakdown caused by increased 
HO-1 after I/R. We also showed that HO-1 is implicated in 
early graft function during LDLT. Furthermore, a possibility 
exists that the extent of early graft dysfunction is partly affected 
by HO-1 expression in the grafted liver.
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